Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Jan;51(1):61-70.
doi: 10.1046/j.1365-2125.2001.01301.x.

Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy

A D Huitema  1 , R A Mathôt, M M Tibben, J H Schellens, S Rodenhuis, J H Beijnen
Affiliations

Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy

A D Huitema et al. Br J Clin Pharmacol. 2001 Jan.

Abstract

Aims: To study the population pharmacokinetics of thioTEPA and its main metabolite TEPA in patients receiving high-dose chemotherapy consisting of thioTEPA (80-120 mg x m(-2) x day(-1)), cyclophosphamide (1000-1500 mg x m(-2) x day(-1)) and carboplatin (265-400 mg x m(-2) x day(-1)) for 4 days.

Methods: ThioTEPA and TEPA kinetic data were processed with a two-compartment model using the nonlinear mixed effect modelling program NONMEM. Interindividual variability (IIV), interoccasion variability (IOV) and residual variability in the pharmacokinetics were estimated. The influence of patient characteristics on the pharmacokinetics was also determined.

Results: A total number of 40 patients receiving 65 courses of chemotherapy was included. Clearance of thioTEPA (CL) was 34 l x h(-1) with an IIV and IOV of 18 and 11%, respectively. The volume of distribution of thioTEPA was 47 l (IIV = 7.5%; IOV = 19%). The fraction of thioTEPA converted to TEPA divided by the volume of distribution of TEPA was 0.030 l-1 (IIV = 39%; IOV = 32%) and the elimination rate constant of TEPA was 0.64 h(-1) (IIV = 27%; IOV = 32%). CL of thioTEPA was correlated with alkaline phosphatase and serum albumin. The volume of distribution of thioTEPA and the elimination rate constant of TEPA were correlated with total protein levels and body weight, respectively.

Conclusions: A model for the description of the pharmacokinetics of thioTEPA and TEPA was developed. Factors involved in the interpatient variability of thioTEPA and TEPA pharmacokinetics were identified. Since, IOV of both thioTEPA and TEPA was equal to or smaller than IIV, therapeutic drug monitoring based on data of previous courses may be meaningful using this population model.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Chemical structures of thioTEPA and its main metabolite TEPA.
Figure 2
Figure 2
Schematic representation of the basic pharmacokinetic model.
Figure 3
Figure 3
Concentration-time data and fitted curves for thioTEPA (solid line and •) and TEPA (dashed line and □) in a representative patient.
Figure 4
Figure 4
Weighted residuals vs the predicted concentrations of the basic pharmacokinetic model for thioTEPA (a) and TEPA (b).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sykes M, Karnofsky D, Phillips F, Burchenal J. Clinical studies of triethylenethiophosphoramide and diethylenephosphoramide compounds with nitrogen mustard-like activity. Cancer. 1953;6:61–70.
    1. van der Wall E, Beijnen JH, Rodenhuis S. High-dose chemotherapy for solid tumors. Cancer Treat Rev. 1995;21:105–132. - PubMed
    1. Cole DE, Johnson G, Tartaglia RL, O'Dwyer P, Balis F, Poplack DG. Correlation between plasma pharmacokinetics and in vitro cytotoxicity of thiotepa (tt) and tepa (tp) Proc Am Ass Clin Oncol. 1989;8:72.
    1. Breau AP, Field L, Mitchell WM. Thiono compounds. 4. in vitro mutagenic and antineoplastic activity of tepa and thio-tepa. Cell Biol Toxicol. 1984;1:21–30. - PubMed
    1. Teicher BA, Waxman DJ, Holden SA, et al. Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity of N,N',N′′-triethylenethiophosphoramide. Cancer Res. 1989;49:4996–5001. - PubMed

Publication types